Skip to main content
Back
VCYT logo

Veracyte, Inc.

Data quality: 100%
VCYT
NASDAQ Healthcare Biotechnology
$33.54
▲ $1.70 (5.34%)
Mkt Cap: 2.67B
Day Range
$32.08 $33.81
52-Week Range
$22.61 $50.71
Volume
1,235,624
50D / 200D Avg
$37.13 / $34.68
Prev Close
$31.84

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E 40.2 0.4
P/B 2.0 2.9
ROE % 5.3 3.8
Net Margin % 12.8 3.9
Rev Growth 5Y % 23.9 10.0
D/E 0.0 0.2

Key Takeaways

Revenue grew 23.89% annually over 5 years — strong growth
Earnings grew 174.89% over the past year
Debt/Equity of 0.03 — conservative balance sheet
Generating 126.63M in free cash flow
P/E of 40.16 — premium valuation
PEG of 0.31 suggests growth is underpriced

Growth

Revenue Growth (5Y)
23.89%
Revenue (1Y)16.01%
Earnings (1Y)174.89%
FCF Growth (3Y)92.25%

Quality

Return on Equity
5.34%
ROIC4.12%
Net Margin12.83%
Op. Margin14.34%

Safety

Debt / Equity
0.03
Current Ratio8.15
Interest Coverage0.00

Valuation

P/E Ratio
40.16
P/B Ratio2.04
EV/EBITDA31.59
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 16.01% Revenue Growth (3Y) 19.68%
Earnings Growth (1Y) 174.89% Earnings Growth (3Y) N/A
Revenue Growth (5Y) 23.89% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 517.15M Net Income (TTM) 66.35M
ROE 5.34% ROA 4.72%
Gross Margin 69.62% Operating Margin 14.34%
Net Margin 12.83% Free Cash Flow (TTM) 126.63M
ROIC 4.12% FCF Growth (3Y) 92.25%
Safety
Debt / Equity 0.03 Current Ratio 8.15
Interest Coverage 0.00 Dividend Yield 0.00%
Valuation
P/E Ratio 40.16 P/B Ratio 2.04
P/S Ratio 5.15 PEG Ratio 0.31
EV/EBITDA 31.59 Dividend Yield 0.00%
Market Cap 2.67B Enterprise Value 2.34B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 517.15M 445.76M 361.05M 296.54M 219.51M
Net Income 66.35M 24.14M -74.40M -36.56M -75.56M
EPS (Diluted) 0.82 0.31 -1.02 -0.51 -1.11
Gross Profit 360.05M 298.15M 248.15M 194.95M 145.11M
Operating Income 74.15M 16.14M -85.80M -41.08M -81.90M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1.41B 1.30B 1.11B 1.16B 1.19B
Total Liabilities 96.44M 124.07M 70.80M 81.22M 91.31M
Shareholders' Equity 1.31B 1.18B 1.04B 1.08B 1.10B
Total Debt 39.65M 50.74M 12.63M 14.72M 18.85M
Cash & Equivalents 362.58M 239.09M 216.45M 154.25M 173.20M
Current Assets 488.38M 372.27M 285.62M 248.64M 243.10M
Current Liabilities 59.94M 78.63M 61.24M 62.61M 64.15M

Strategy Scores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
#829 of 1024
29

Recent Activity

Entered Cash Flow Compounder
Mar 24, 2026